Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Potassium Bromide→

Potassium Bromide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7758-02-3
Molecular formula
BrK
Molecular weight
119 g/mol
Drug class
Inorganic potassium saltbromide ion anticonvulsant (primarily veterinary use)
Mechanism of action
Bromide ions substitute for chloride in neuronal conductance and increase inhibitory neuronal tone, reducing neuronal excitability. Potassium is the counter-ion; the pharmacological anticonvulsant moiety is bromide.
Indications / reported uses
  • Anticonvulsant treatment of epilepsy in dogs in veterinary practice where authorised; human therapeutic use is historical or highly restricted and should not be inferred from veterinary product information

Sources: PubMed — Potassium bromide in canine epilepsy · NLM MeSH — Potassium bromide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Potassium Bromide Environmental Risk Assessment (ERA) (the Potassium Bromide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.